chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Heart rate, Heart rate increased, Nausea, Rash, SARS-CoV-2 test
Clinical narrative: Flushed; over heated; rash/hives on chest; rash/hives on chest; dry mouth; swollen tongue; rapid heart rate; nausea; headache; weakness; This is a spontaneous report from a contactable consumer (patient). A 44-year-old female patient  received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number: EL9261), via an unspecified route of administration on 21Jan2021 at 16:00 at a single dose in the left arm for COVID-19 immunization. Medical history included seasonal allergies, some environmental allergies, some heart issues specified as SVT, slight asthma, and lung damage. Prior to vaccination, the patient was diagnosed with COVID-19 on 26Dec2020 (also reported as possibly had COVID in Mar2020, however no tests were available; patient was told to quarantine). On 31Dec2020, COVID-19 test showed a positive result. The patient recovered on 09Jan2021, two weeks from onset of symptoms. The patient's concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine and was not pregnant at the time of vaccination. On 21Jan2021 at 16:15, the patient experienced the following adverse events: flushed, over heated, rash/hives on chest, dry mouth, swollen tongue, rapid heart rate, nausea, headache, and weakness. The events resulted to emergency room visit and doctor office visit. The patient received two epi shots, allergy and anti-nausea medications as treatment for the events. Since the vaccination, the patient has not been tested for COVID-19. The outcome of the events was recovered on an unspecified date.
Age: 44.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Swollen tongue, Urticaria
Clinical narrative: Flushed; over heated; rash/hives on chest; rash/hives on chest; dry mouth; swollen tongue; rapid heart rate; nausea; headache; weakness; This is a spontaneous report from a contactable consumer (patient). A 44-year-old female patient  received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number: EL9261), via an unspecified route of administration on 21Jan2021 at 16:00 at a single dose in the left arm for COVID-19 immunization. Medical history included seasonal allergies, some environmental allergies, some heart issues specified as SVT, slight asthma, and lung damage. Prior to vaccination, the patient was diagnosed with COVID-19 on 26Dec2020 (also reported as possibly had COVID in Mar2020, however no tests were available; patient was told to quarantine). On 31Dec2020, COVID-19 test showed a positive result. The patient recovered on 09Jan2021, two weeks from onset of symptoms. The patient's concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine and was not pregnant at the time of vaccination. On 21Jan2021 at 16:15, the patient experienced the following adverse events: flushed, over heated, rash/hives on chest, dry mouth, swollen tongue, rapid heart rate, nausea, headache, and weakness. The events resulted to emergency room visit and doctor office visit. The patient received two epi shots, allergy and anti-nausea medications as treatment for the events. Since the vaccination, the patient has not been tested for COVID-19. The outcome of the events was recovered on an unspecified date.
Age: 54.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Cough, Dysphonia, Dyspnoea, Flushing, Hypoaesthesia
Clinical narrative: difficulty inhaling; cough; hives; tongue and lips tingling; tongue and lips tingling; itching; This is a spontaneous report from a contactable nurse reporting for herself. A 54-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE) (lot number EL 3246/expiration date: not provided), via an unspecified route of administration, on 15Jan2021 at 08:00 (at the age of 54 years old) as a single dose in the left arm for COVID-19 IMMUNIZATION. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE) (lot number EL1284/expiration date: not provided), via an unspecified route of administration, on 26Dec2020 at 10:00 (at the age of 54 years old) as a single dose in the left arm for COVID-19 IMMUNIZATION. Relevant medical history included exercised induced asthma, and psoriatic eczema. The patient had known allergies to penicillin, fentanyl, and levofloxacin (LEVAQUIN). Concomitant medication included levothyroxine sodium (SYNTHROID) and atorvastatin (LIPITOR). The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 15Jan2021 at 08:15, the patient experienced difficulty inhaling, cough, hives, itching, tongue and lips tingling. The events resulted in an emergency room visit. The patient received treatment for these events which included treatment epi: IV fluids, IV benadryl, Pepcid, Solumedrol then IM. The outcome of the events difficulty inhaling, cough, hives, itching, tongue and lips tingling was recovered with lasting effects (sequel) on an unspecified date in 2021. Since the vaccination, the patient had not been tested for COVID-19.
Age: 54.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Paraesthesia, Wheezing
Clinical narrative: difficulty inhaling; cough; hives; tongue and lips tingling; tongue and lips tingling; itching; This is a spontaneous report from a contactable nurse reporting for herself. A 54-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE) (lot number EL 3246/expiration date: not provided), via an unspecified route of administration, on 15Jan2021 at 08:00 (at the age of 54 years old) as a single dose in the left arm for COVID-19 IMMUNIZATION. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE) (lot number EL1284/expiration date: not provided), via an unspecified route of administration, on 26Dec2020 at 10:00 (at the age of 54 years old) as a single dose in the left arm for COVID-19 IMMUNIZATION. Relevant medical history included exercised induced asthma, and psoriatic eczema. The patient had known allergies to penicillin, fentanyl, and levofloxacin (LEVAQUIN). Concomitant medication included levothyroxine sodium (SYNTHROID) and atorvastatin (LIPITOR). The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 15Jan2021 at 08:15, the patient experienced difficulty inhaling, cough, hives, itching, tongue and lips tingling. The events resulted in an emergency room visit. The patient received treatment for these events which included treatment epi: IV fluids, IV benadryl, Pepcid, Solumedrol then IM. The outcome of the events difficulty inhaling, cough, hives, itching, tongue and lips tingling was recovered with lasting effects (sequel) on an unspecified date in 2021. Since the vaccination, the patient had not been tested for COVID-19.
Age: 54.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Blood pressure normal, Cough, Dizziness, Dyspnoea, Full blood count normal
Clinical narrative: difficulty inhaling; cough; hives; tongue and lips tingling; tongue and lips tingling; itching; This is a spontaneous report from a contactable nurse reporting for herself. A 54-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE) (lot number EL 3246/expiration date: not provided), via an unspecified route of administration, on 15Jan2021 at 08:00 (at the age of 54 years old) as a single dose in the left arm for COVID-19 IMMUNIZATION. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE) (lot number EL1284/expiration date: not provided), via an unspecified route of administration, on 26Dec2020 at 10:00 (at the age of 54 years old) as a single dose in the left arm for COVID-19 IMMUNIZATION. Relevant medical history included exercised induced asthma, and psoriatic eczema. The patient had known allergies to penicillin, fentanyl, and levofloxacin (LEVAQUIN). Concomitant medication included levothyroxine sodium (SYNTHROID) and atorvastatin (LIPITOR). The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 15Jan2021 at 08:15, the patient experienced difficulty inhaling, cough, hives, itching, tongue and lips tingling. The events resulted in an emergency room visit. The patient received treatment for these events which included treatment epi: IV fluids, IV benadryl, Pepcid, Solumedrol then IM. The outcome of the events difficulty inhaling, cough, hives, itching, tongue and lips tingling was recovered with lasting effects (sequel) on an unspecified date in 2021. Since the vaccination, the patient had not been tested for COVID-19.
Age: 54.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Hypoaesthesia, Paraesthesia oral, Pruritus, Urticaria, Wheezing
Clinical narrative: difficulty inhaling; cough; hives; tongue and lips tingling; tongue and lips tingling; itching; This is a spontaneous report from a contactable nurse reporting for herself. A 54-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE) (lot number EL 3246/expiration date: not provided), via an unspecified route of administration, on 15Jan2021 at 08:00 (at the age of 54 years old) as a single dose in the left arm for COVID-19 IMMUNIZATION. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE) (lot number EL1284/expiration date: not provided), via an unspecified route of administration, on 26Dec2020 at 10:00 (at the age of 54 years old) as a single dose in the left arm for COVID-19 IMMUNIZATION. Relevant medical history included exercised induced asthma, and psoriatic eczema. The patient had known allergies to penicillin, fentanyl, and levofloxacin (LEVAQUIN). Concomitant medication included levothyroxine sodium (SYNTHROID) and atorvastatin (LIPITOR). The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 15Jan2021 at 08:15, the patient experienced difficulty inhaling, cough, hives, itching, tongue and lips tingling. The events resulted in an emergency room visit. The patient received treatment for these events which included treatment epi: IV fluids, IV benadryl, Pepcid, Solumedrol then IM. The outcome of the events difficulty inhaling, cough, hives, itching, tongue and lips tingling was recovered with lasting effects (sequel) on an unspecified date in 2021. Since the vaccination, the patient had not been tested for COVID-19.
Age: 54.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Cough, Dyspnoea, Paraesthesia oral, Pruritus, Urticaria
Clinical narrative: difficulty inhaling; cough; hives; tongue and lips tingling; tongue and lips tingling; itching; This is a spontaneous report from a contactable nurse reporting for herself. A 54-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE) (lot number EL 3246/expiration date: not provided), via an unspecified route of administration, on 15Jan2021 at 08:00 (at the age of 54 years old) as a single dose in the left arm for COVID-19 IMMUNIZATION. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE) (lot number EL1284/expiration date: not provided), via an unspecified route of administration, on 26Dec2020 at 10:00 (at the age of 54 years old) as a single dose in the left arm for COVID-19 IMMUNIZATION. Relevant medical history included exercised induced asthma, and psoriatic eczema. The patient had known allergies to penicillin, fentanyl, and levofloxacin (LEVAQUIN). Concomitant medication included levothyroxine sodium (SYNTHROID) and atorvastatin (LIPITOR). The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 15Jan2021 at 08:15, the patient experienced difficulty inhaling, cough, hives, itching, tongue and lips tingling. The events resulted in an emergency room visit. The patient received treatment for these events which included treatment epi: IV fluids, IV benadryl, Pepcid, Solumedrol then IM. The outcome of the events difficulty inhaling, cough, hives, itching, tongue and lips tingling was recovered with lasting effects (sequel) on an unspecified date in 2021. Since the vaccination, the patient had not been tested for COVID-19.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Brachial plexopathy, Electromyogram, Magnetic resonance imaging, Magnetic resonance imaging neck, Muscle spasms
Clinical narrative: Brachial plexopathy; This is a spontaneous report from a  sponsored program from a contactable physician (patient).   A patient of an unspecified age and gender received the first dose of BNT162B2 (Pfizer-Biontech Covid-19 Vaccine) at single dose, on an unspecified date, for COVID-19 immunisation. Relevant medical history and concomitant medications were unknown. On an unspecified date, the patient experienced brachial plexopathy. It was reported that the patient did not take the second dose. Clinical outcome of the adverse event was unknown at time of this report.   Information on the lot/batch number has been requested.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Muscular weakness, Paraesthesia
Clinical narrative: Brachial plexopathy; This is a spontaneous report from a  sponsored program from a contactable physician (patient).   A patient of an unspecified age and gender received the first dose of BNT162B2 (Pfizer-Biontech Covid-19 Vaccine) at single dose, on an unspecified date, for COVID-19 immunisation. Relevant medical history and concomitant medications were unknown. On an unspecified date, the patient experienced brachial plexopathy. It was reported that the patient did not take the second dose. Clinical outcome of the adverse event was unknown at time of this report.   Information on the lot/batch number has been requested.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Brachial plexopathy
Clinical narrative: Brachial plexopathy; This is a spontaneous report from a  sponsored program from a contactable physician (patient).   A patient of an unspecified age and gender received the first dose of BNT162B2 (Pfizer-Biontech Covid-19 Vaccine) at single dose, on an unspecified date, for COVID-19 immunisation. Relevant medical history and concomitant medications were unknown. On an unspecified date, the patient experienced brachial plexopathy. It was reported that the patient did not take the second dose. Clinical outcome of the adverse event was unknown at time of this report.   Information on the lot/batch number has been requested.
Age: 32.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Chills, Feeling abnormal, Hypertension, Nausea, Vomiting
Clinical narrative: Large red , raised circle, chills, tired. No feveR
Age: 32.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Chills, Erythema, Fatigue, Swelling, Vaccination complication
Clinical narrative: Large red , raised circle, chills, tired. No feveR
Age: 38.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Amnesia, Asthenia, Balance disorder, Computerised tomogram head, Coordination abnormal
Clinical narrative: symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; This is a spontaneous report from a contactable Other HCP. A 38-year-old non-pregnant female received first dose BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on 13Jan2021 (Lot number: EL3302) via intramuscular route of administration at SINGLE DOSE for COVID-19 Immunization. The patient's medical history included environmental allergies, Type 2 diabetes mellitus, Mixed hyperlipidemia, Attention deficit hyperactivity disorder, Obesity and Anxiety from an unknown date and unknown if ongoing. Concomitant medications included atorvastatin calcium at 20mg, Desogestrel/Ethinylestradiol (Azurette) at (23) 0.15mg-0.02mg (21)/0.07mg (S), clotrimazole and betamethasone at 1%-5%, cyclobenzaprine at 10mg, escitalopram oxalate (lexapro) at 20mg, metformin at 500mg, esomeprazole magnesium (nexium) at 20mg, montelukast sodium (singulair) at 10mg, amfetamine aspartate/amfetamine sulfate/dexamfetamine saccharate/dexamfetamine sulfate (Adderall) at 20 mg, cetirizine hydrochloride (zyrtec) at 10 mg, fluticasone proplonate at 50mcg. It was unknown if the patient had illnesses at the time of vaccination and up to one month prior. Patient was seen in office on 27Jan2021 and reported symptoms of Headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors causing change in handwriting for the past 1.5 to 2 weeks after receiving vaccination. Upon review of Neurological symptom, patient was positive for loss of balance and coordination 4/5 strength. In all extremities, and 4/5 grip strength, CT of Head with and W/O contrast was ordered. CBC, CMP, free T4, HgbA1c, lipid, 'TSH, Urinalysis, Vitamin B12, Folate and CK laboratory ordered. CT Head with and w/o Contrast on 27Jan2021 showed no acute intracranial process Identified. No evidence of enhancing lesion. Patient had not completed laboratory at this time. It was unknown if the patient had doctor or other healthcare professional office/clinic visit. The outcome of the event was not recovered.  No follow-up attempts are possible. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dizziness, Headache, Muscular weakness, Speech disorder, Tremor
Clinical narrative: symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; This is a spontaneous report from a contactable Other HCP. A 38-year-old non-pregnant female received first dose BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on 13Jan2021 (Lot number: EL3302) via intramuscular route of administration at SINGLE DOSE for COVID-19 Immunization. The patient's medical history included environmental allergies, Type 2 diabetes mellitus, Mixed hyperlipidemia, Attention deficit hyperactivity disorder, Obesity and Anxiety from an unknown date and unknown if ongoing. Concomitant medications included atorvastatin calcium at 20mg, Desogestrel/Ethinylestradiol (Azurette) at (23) 0.15mg-0.02mg (21)/0.07mg (S), clotrimazole and betamethasone at 1%-5%, cyclobenzaprine at 10mg, escitalopram oxalate (lexapro) at 20mg, metformin at 500mg, esomeprazole magnesium (nexium) at 20mg, montelukast sodium (singulair) at 10mg, amfetamine aspartate/amfetamine sulfate/dexamfetamine saccharate/dexamfetamine sulfate (Adderall) at 20 mg, cetirizine hydrochloride (zyrtec) at 10 mg, fluticasone proplonate at 50mcg. It was unknown if the patient had illnesses at the time of vaccination and up to one month prior. Patient was seen in office on 27Jan2021 and reported symptoms of Headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors causing change in handwriting for the past 1.5 to 2 weeks after receiving vaccination. Upon review of Neurological symptom, patient was positive for loss of balance and coordination 4/5 strength. In all extremities, and 4/5 grip strength, CT of Head with and W/O contrast was ordered. CBC, CMP, free T4, HgbA1c, lipid, 'TSH, Urinalysis, Vitamin B12, Folate and CK laboratory ordered. CT Head with and w/o Contrast on 27Jan2021 showed no acute intracranial process Identified. No evidence of enhancing lesion. Patient had not completed laboratory at this time. It was unknown if the patient had doctor or other healthcare professional office/clinic visit. The outcome of the event was not recovered.  No follow-up attempts are possible. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Amnesia, Balance disorder, Balance test, Blood creatine phosphokinase, Blood folate
Clinical narrative: symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; This is a spontaneous report from a contactable Other HCP. A 38-year-old non-pregnant female received first dose BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on 13Jan2021 (Lot number: EL3302) via intramuscular route of administration at SINGLE DOSE for COVID-19 Immunization. The patient's medical history included environmental allergies, Type 2 diabetes mellitus, Mixed hyperlipidemia, Attention deficit hyperactivity disorder, Obesity and Anxiety from an unknown date and unknown if ongoing. Concomitant medications included atorvastatin calcium at 20mg, Desogestrel/Ethinylestradiol (Azurette) at (23) 0.15mg-0.02mg (21)/0.07mg (S), clotrimazole and betamethasone at 1%-5%, cyclobenzaprine at 10mg, escitalopram oxalate (lexapro) at 20mg, metformin at 500mg, esomeprazole magnesium (nexium) at 20mg, montelukast sodium (singulair) at 10mg, amfetamine aspartate/amfetamine sulfate/dexamfetamine saccharate/dexamfetamine sulfate (Adderall) at 20 mg, cetirizine hydrochloride (zyrtec) at 10 mg, fluticasone proplonate at 50mcg. It was unknown if the patient had illnesses at the time of vaccination and up to one month prior. Patient was seen in office on 27Jan2021 and reported symptoms of Headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors causing change in handwriting for the past 1.5 to 2 weeks after receiving vaccination. Upon review of Neurological symptom, patient was positive for loss of balance and coordination 4/5 strength. In all extremities, and 4/5 grip strength, CT of Head with and W/O contrast was ordered. CBC, CMP, free T4, HgbA1c, lipid, 'TSH, Urinalysis, Vitamin B12, Folate and CK laboratory ordered. CT Head with and w/o Contrast on 27Jan2021 showed no acute intracranial process Identified. No evidence of enhancing lesion. Patient had not completed laboratory at this time. It was unknown if the patient had doctor or other healthcare professional office/clinic visit. The outcome of the event was not recovered.  No follow-up attempts are possible. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood thyroid stimulating hormone, Computerised tomogram, Dizziness, Full blood count, Glycosylated haemoglobin
Clinical narrative: symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; This is a spontaneous report from a contactable Other HCP. A 38-year-old non-pregnant female received first dose BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on 13Jan2021 (Lot number: EL3302) via intramuscular route of administration at SINGLE DOSE for COVID-19 Immunization. The patient's medical history included environmental allergies, Type 2 diabetes mellitus, Mixed hyperlipidemia, Attention deficit hyperactivity disorder, Obesity and Anxiety from an unknown date and unknown if ongoing. Concomitant medications included atorvastatin calcium at 20mg, Desogestrel/Ethinylestradiol (Azurette) at (23) 0.15mg-0.02mg (21)/0.07mg (S), clotrimazole and betamethasone at 1%-5%, cyclobenzaprine at 10mg, escitalopram oxalate (lexapro) at 20mg, metformin at 500mg, esomeprazole magnesium (nexium) at 20mg, montelukast sodium (singulair) at 10mg, amfetamine aspartate/amfetamine sulfate/dexamfetamine saccharate/dexamfetamine sulfate (Adderall) at 20 mg, cetirizine hydrochloride (zyrtec) at 10 mg, fluticasone proplonate at 50mcg. It was unknown if the patient had illnesses at the time of vaccination and up to one month prior. Patient was seen in office on 27Jan2021 and reported symptoms of Headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors causing change in handwriting for the past 1.5 to 2 weeks after receiving vaccination. Upon review of Neurological symptom, patient was positive for loss of balance and coordination 4/5 strength. In all extremities, and 4/5 grip strength, CT of Head with and W/O contrast was ordered. CBC, CMP, free T4, HgbA1c, lipid, 'TSH, Urinalysis, Vitamin B12, Folate and CK laboratory ordered. CT Head with and w/o Contrast on 27Jan2021 showed no acute intracranial process Identified. No evidence of enhancing lesion. Patient had not completed laboratory at this time. It was unknown if the patient had doctor or other healthcare professional office/clinic visit. The outcome of the event was not recovered.  No follow-up attempts are possible. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Grip strength, Headache, Lipids, Metabolic function test, Speech disorder
Clinical narrative: symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; This is a spontaneous report from a contactable Other HCP. A 38-year-old non-pregnant female received first dose BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on 13Jan2021 (Lot number: EL3302) via intramuscular route of administration at SINGLE DOSE for COVID-19 Immunization. The patient's medical history included environmental allergies, Type 2 diabetes mellitus, Mixed hyperlipidemia, Attention deficit hyperactivity disorder, Obesity and Anxiety from an unknown date and unknown if ongoing. Concomitant medications included atorvastatin calcium at 20mg, Desogestrel/Ethinylestradiol (Azurette) at (23) 0.15mg-0.02mg (21)/0.07mg (S), clotrimazole and betamethasone at 1%-5%, cyclobenzaprine at 10mg, escitalopram oxalate (lexapro) at 20mg, metformin at 500mg, esomeprazole magnesium (nexium) at 20mg, montelukast sodium (singulair) at 10mg, amfetamine aspartate/amfetamine sulfate/dexamfetamine saccharate/dexamfetamine sulfate (Adderall) at 20 mg, cetirizine hydrochloride (zyrtec) at 10 mg, fluticasone proplonate at 50mcg. It was unknown if the patient had illnesses at the time of vaccination and up to one month prior. Patient was seen in office on 27Jan2021 and reported symptoms of Headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors causing change in handwriting for the past 1.5 to 2 weeks after receiving vaccination. Upon review of Neurological symptom, patient was positive for loss of balance and coordination 4/5 strength. In all extremities, and 4/5 grip strength, CT of Head with and W/O contrast was ordered. CBC, CMP, free T4, HgbA1c, lipid, 'TSH, Urinalysis, Vitamin B12, Folate and CK laboratory ordered. CT Head with and w/o Contrast on 27Jan2021 showed no acute intracranial process Identified. No evidence of enhancing lesion. Patient had not completed laboratory at this time. It was unknown if the patient had doctor or other healthcare professional office/clinic visit. The outcome of the event was not recovered.  No follow-up attempts are possible. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Thyroxine free, Tremor, Urine analysis, Vitamin B12
Clinical narrative: symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; symptoms of headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors; This is a spontaneous report from a contactable Other HCP. A 38-year-old non-pregnant female received first dose BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on 13Jan2021 (Lot number: EL3302) via intramuscular route of administration at SINGLE DOSE for COVID-19 Immunization. The patient's medical history included environmental allergies, Type 2 diabetes mellitus, Mixed hyperlipidemia, Attention deficit hyperactivity disorder, Obesity and Anxiety from an unknown date and unknown if ongoing. Concomitant medications included atorvastatin calcium at 20mg, Desogestrel/Ethinylestradiol (Azurette) at (23) 0.15mg-0.02mg (21)/0.07mg (S), clotrimazole and betamethasone at 1%-5%, cyclobenzaprine at 10mg, escitalopram oxalate (lexapro) at 20mg, metformin at 500mg, esomeprazole magnesium (nexium) at 20mg, montelukast sodium (singulair) at 10mg, amfetamine aspartate/amfetamine sulfate/dexamfetamine saccharate/dexamfetamine sulfate (Adderall) at 20 mg, cetirizine hydrochloride (zyrtec) at 10 mg, fluticasone proplonate at 50mcg. It was unknown if the patient had illnesses at the time of vaccination and up to one month prior. Patient was seen in office on 27Jan2021 and reported symptoms of Headache, dizziness, speech disturbance, memory loss, balance issue, and hand tremors causing change in handwriting for the past 1.5 to 2 weeks after receiving vaccination. Upon review of Neurological symptom, patient was positive for loss of balance and coordination 4/5 strength. In all extremities, and 4/5 grip strength, CT of Head with and W/O contrast was ordered. CBC, CMP, free T4, HgbA1c, lipid, 'TSH, Urinalysis, Vitamin B12, Folate and CK laboratory ordered. CT Head with and w/o Contrast on 27Jan2021 showed no acute intracranial process Identified. No evidence of enhancing lesion. Patient had not completed laboratory at this time. It was unknown if the patient had doctor or other healthcare professional office/clinic visit. The outcome of the event was not recovered.  No follow-up attempts are possible. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Asthenia, Fatigue, Pyrexia, Urticaria
Clinical narrative: Severe hives from chest down 3 days later; This is a spontaneous report from a contactable consumer (patient). A 33-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) Lot number Elo142, on 02Feb2021 17:00 at single dose in left arm for COVID-19 immunization. Medical history was not reported. Concomitant medication was none. The patient previously received first dose of BNT162B2 (Lot number= El9264 or 9) on 12Jan2021 04:30 AM in left arm. The patient had no other vaccine in four weeks. The patient had no covid prior vaccination. The patient had no covid tested post vaccination. The patient had no known allergies. The patient had Severe hives from chest down 3 days later on 05Feb2021 20:30. The event resulted in Emergency room/department or urgent care. Treatment received for the event included Steroid shots and package. The outcome of the event was resolving.
Age: 33.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Urticaria
Clinical narrative: Severe hives from chest down 3 days later; This is a spontaneous report from a contactable consumer (patient). A 33-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) Lot number Elo142, on 02Feb2021 17:00 at single dose in left arm for COVID-19 immunization. Medical history was not reported. Concomitant medication was none. The patient previously received first dose of BNT162B2 (Lot number= El9264 or 9) on 12Jan2021 04:30 AM in left arm. The patient had no other vaccine in four weeks. The patient had no covid prior vaccination. The patient had no covid tested post vaccination. The patient had no known allergies. The patient had Severe hives from chest down 3 days later on 05Feb2021 20:30. The event resulted in Emergency room/department or urgent care. Treatment received for the event included Steroid shots and package. The outcome of the event was resolving.
Age: 63.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Body temperature increased, Headache, Myalgia, Pruritus, Tongue disorder
Clinical narrative: Thickening of tongue; itching arms,legs,face, head; headache; This is a spontaneous report from a contactable nurse (patient).  A 63-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration at arm right on 06Feb2021 at 12:00 (at the age of 63-year-old) at single dose for COVID-19 immunization. The patient was not pregnant. Medical history included asthma, fibromyalgia, COVID-19 and allergies, all from an unknown date and unknown if ongoing.  Concomitant medication included fluticasone furoate/vilanterol trifenatate (BREO ELLIPTA), tiotropium bromide (SPIRIVA), spironolactone, simvastatin and omeprazole (PROTONIX). On 06Feb2021, the patient experienced thickening of tongue, itching (arms, legs, face, head) and headache. No therapeutic measures were taken as a result of the events. The patient outcome of the events was not recovered.   Information on the lot/batch number has been requested.
Age: 63.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Headache, Pruritus, Swollen tongue
Clinical narrative: Thickening of tongue; itching arms,legs,face, head; headache; This is a spontaneous report from a contactable nurse (patient).  A 63-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration at arm right on 06Feb2021 at 12:00 (at the age of 63-year-old) at single dose for COVID-19 immunization. The patient was not pregnant. Medical history included asthma, fibromyalgia, COVID-19 and allergies, all from an unknown date and unknown if ongoing.  Concomitant medication included fluticasone furoate/vilanterol trifenatate (BREO ELLIPTA), tiotropium bromide (SPIRIVA), spironolactone, simvastatin and omeprazole (PROTONIX). On 06Feb2021, the patient experienced thickening of tongue, itching (arms, legs, face, head) and headache. No therapeutic measures were taken as a result of the events. The patient outcome of the events was not recovered.   Information on the lot/batch number has been requested.
Age: 68.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Chills, Swelling face
Clinical narrative: I didn't sleep last night; parts of face and under chine was swollen; BP102 at 3pm blood pressure was 132/82; This is a spontaneous report from a contactable Other HCP. A 68-year-old male patient received first dose of BNT162B2(PFIZER-BIONTECH COVID-19 VACCINE, Lot number: EL9261), via an unspecified route of administration on 05Feb2021 08:15 at single dose, right arm for COVID-19 immunization. Medical history included high blood pressure, Crohn's disease and mental health issues. Known allergies included valproate semisodium(DEPAKOTE) and fluoxetine hydrochloride(PROZAC). The patient's concomitant medications were not reported. The patient didn't sleep last night. Parts of face and under chine was swollen, blood pressure(BP) 102 at 3pm blood pressure was 132/82. Noticed after waking up at 2:30PM. The patient went to sleep at 9:30pm. Events start date was 05Feb2021, 03:00PM. Events resulted in: Doctor or other healthcare professional office/clinic visit. There was no covid prior vaccination, no covid tested post vaccination. No treatment received for the events. The outcome of the events was recovering.
Age: 68.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Blood pressure increased, Blood pressure measurement, Sleep disorder, Swelling face
Clinical narrative: I didn't sleep last night; parts of face and under chine was swollen; BP102 at 3pm blood pressure was 132/82; This is a spontaneous report from a contactable Other HCP. A 68-year-old male patient received first dose of BNT162B2(PFIZER-BIONTECH COVID-19 VACCINE, Lot number: EL9261), via an unspecified route of administration on 05Feb2021 08:15 at single dose, right arm for COVID-19 immunization. Medical history included high blood pressure, Crohn's disease and mental health issues. Known allergies included valproate semisodium(DEPAKOTE) and fluoxetine hydrochloride(PROZAC). The patient's concomitant medications were not reported. The patient didn't sleep last night. Parts of face and under chine was swollen, blood pressure(BP) 102 at 3pm blood pressure was 132/82. Noticed after waking up at 2:30PM. The patient went to sleep at 9:30pm. Events start date was 05Feb2021, 03:00PM. Events resulted in: Doctor or other healthcare professional office/clinic visit. There was no covid prior vaccination, no covid tested post vaccination. No treatment received for the events. The outcome of the events was recovering.
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Abdominal pain upper, Asthenia, Dysgeusia, Headache, Nausea
Clinical narrative: At 8pm began having headaches. At 10pm lost taste and smell, started experiencing body aches, abdominal pain and nausea for 3 days. Took Tylenol for pain and Famotidine and Pepto Bismol for nausea. As of 3/1/21 all symptoms relieved except for smell and taste.
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pain, Pain in extremity
Clinical narrative: At 8pm began having headaches. At 10pm lost taste and smell, started experiencing body aches, abdominal pain and nausea for 3 days. Took Tylenol for pain and Famotidine and Pepto Bismol for nausea. As of 3/1/21 all symptoms relieved except for smell and taste.
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Abdominal pain, Ageusia, Anosmia, Headache, Nausea
Clinical narrative: At 8pm began having headaches. At 10pm lost taste and smell, started experiencing body aches, abdominal pain and nausea for 3 days. Took Tylenol for pain and Famotidine and Pepto Bismol for nausea. As of 3/1/21 all symptoms relieved except for smell and taste.
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pain
Clinical narrative: At 8pm began having headaches. At 10pm lost taste and smell, started experiencing body aches, abdominal pain and nausea for 3 days. Took Tylenol for pain and Famotidine and Pepto Bismol for nausea. As of 3/1/21 all symptoms relieved except for smell and taste.
Age: 31.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Axillary pain, Palpitations
Clinical narrative: patient stated palpitation under left arm no chest pain no shortness of breath o2 sat 99-98% on room air bp 130/105 second set of vitals 125/95 patient in no acute distreress . Emotional support given. 3rd set of vitals P 88, BP128/82, o2 99%. Patient continues to report pain to left auxiliary area, was taken to ED for follow up ..
Age: 75.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Body temperature, Chills, Cough, Feeling abnormal, Headache
Clinical narrative: Tested positive for Covid-19  Headache, fever, body chills and aches, loss of smell and taste, nausea, loss of appetite, cough was initial symptom with above following on January 24. Test was positive on January 28. Diagnosed with covid pnemonia on first hospitalization on FEb 5, 2021. Develeped full body active tremors and stutter Feb. 8 re-admitted to ER Feb. 10. GI pain and nausea persisted along with debilitating tremors and stutter. Re-admitted to hospital Feb, 22 for 4 days and transferred to Rehab Clinic for 13 days. Tremors and Gi issues still present as of Feb. 10, 2021
Age: 75.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Nausea, Pain, Parosmia, Pyrexia, SARS-CoV-2 test
Clinical narrative: Tested positive for Covid-19  Headache, fever, body chills and aches, loss of smell and taste, nausea, loss of appetite, cough was initial symptom with above following on January 24. Test was positive on January 28. Diagnosed with covid pnemonia on first hospitalization on FEb 5, 2021. Develeped full body active tremors and stutter Feb. 8 re-admitted to ER Feb. 10. GI pain and nausea persisted along with debilitating tremors and stutter. Re-admitted to hospital Feb, 22 for 4 days and transferred to Rehab Clinic for 13 days. Tremors and Gi issues still present as of Feb. 10, 2021
Age: 75.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Ageusia, Anosmia, COVID-19, COVID-19 pneumonia, Chills
Clinical narrative: Tested positive for Covid-19  Headache, fever, body chills and aches, loss of smell and taste, nausea, loss of appetite, cough was initial symptom with above following on January 24. Test was positive on January 28. Diagnosed with covid pnemonia on first hospitalization on FEb 5, 2021. Develeped full body active tremors and stutter Feb. 8 re-admitted to ER Feb. 10. GI pain and nausea persisted along with debilitating tremors and stutter. Re-admitted to hospital Feb, 22 for 4 days and transferred to Rehab Clinic for 13 days. Tremors and Gi issues still present as of Feb. 10, 2021
Age: 75.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Computerised tomogram head, Computerised tomogram neck, Computerised tomogram thorax, Cough, Decreased appetite
Clinical narrative: Tested positive for Covid-19  Headache, fever, body chills and aches, loss of smell and taste, nausea, loss of appetite, cough was initial symptom with above following on January 24. Test was positive on January 28. Diagnosed with covid pnemonia on first hospitalization on FEb 5, 2021. Develeped full body active tremors and stutter Feb. 8 re-admitted to ER Feb. 10. GI pain and nausea persisted along with debilitating tremors and stutter. Re-admitted to hospital Feb, 22 for 4 days and transferred to Rehab Clinic for 13 days. Tremors and Gi issues still present as of Feb. 10, 2021
Age: 75.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Dysphemia, Electrocardiogram, Gastrointestinal pain, Headache, Magnetic resonance imaging head
Clinical narrative: Tested positive for Covid-19  Headache, fever, body chills and aches, loss of smell and taste, nausea, loss of appetite, cough was initial symptom with above following on January 24. Test was positive on January 28. Diagnosed with covid pnemonia on first hospitalization on FEb 5, 2021. Develeped full body active tremors and stutter Feb. 8 re-admitted to ER Feb. 10. GI pain and nausea persisted along with debilitating tremors and stutter. Re-admitted to hospital Feb, 22 for 4 days and transferred to Rehab Clinic for 13 days. Tremors and Gi issues still present as of Feb. 10, 2021
Age: 75.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Magnetic resonance imaging neck, Nausea, Pain, Pyrexia, SARS-CoV-2 test positive
Clinical narrative: Tested positive for Covid-19  Headache, fever, body chills and aches, loss of smell and taste, nausea, loss of appetite, cough was initial symptom with above following on January 24. Test was positive on January 28. Diagnosed with covid pnemonia on first hospitalization on FEb 5, 2021. Develeped full body active tremors and stutter Feb. 8 re-admitted to ER Feb. 10. GI pain and nausea persisted along with debilitating tremors and stutter. Re-admitted to hospital Feb, 22 for 4 days and transferred to Rehab Clinic for 13 days. Tremors and Gi issues still present as of Feb. 10, 2021
Age: 75.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Tremor
Clinical narrative: Tested positive for Covid-19  Headache, fever, body chills and aches, loss of smell and taste, nausea, loss of appetite, cough was initial symptom with above following on January 24. Test was positive on January 28. Diagnosed with covid pnemonia on first hospitalization on FEb 5, 2021. Develeped full body active tremors and stutter Feb. 8 re-admitted to ER Feb. 10. GI pain and nausea persisted along with debilitating tremors and stutter. Re-admitted to hospital Feb, 22 for 4 days and transferred to Rehab Clinic for 13 days. Tremors and Gi issues still present as of Feb. 10, 2021
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Asthenia, Bone pain, Confusional state, Dehydration, Diarrhoea
Clinical narrative: bone ache; body shaking chills; no appetite; exhaustion; headache; occasional nausea; incapacitating fever; This is a spontaneous report from a contactable consumer, the patient. This 67-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, lot number: EL9265),  dose  2 , single dose via an unspecified route of administration in the left arm on 02Feb2021 at 14:00 (at the age of 67 years-old) for COVID-19 vaccination. The patient was not pregnant.  Medical history included primary immunodeficiency, diabetes, irritable bowel disease, gastroesophageal reflux disease (GERD), high cholesterol and allergy to cefazolin (ANCEF). Historical vaccine included BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, lot number: EL3248, dose 1 on 12Jan2021 at 2:15 PM in the left arm. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included famotidine, lansoprazole, pioglitazone and rosuvastatin. The patient did not receive  any other vaccine within 4 weeks prior to the vaccine. On 03Feb2021 at 09:00 AM, the patient experienced bone ache, body shaking chills, no appetite, exhaustion, headache, occasional nausea and incapacitating fever. Treatment was not received for the events. The clinical outcome of  bone ache, body shaking chills, no appetite, exhaustion, headache, occasional nausea and incapacitating fever was recovering.  It was also reported that since the vaccination, the patient had not been tested for COVID-19.